Safety of new tuberculosis treatment regimens and compliance with these regimens according to data from the Republic of Kazakhstan
https://doi.org/10.58838/2075-1230-2023-101-1-17-26
Abstract
The objective: to assess the safety and compliance with new regimens for preventive treatment of drug susceptible and drug resistant tuberculosis.
Subjects and Methods. The study was carried out in Almaty, the Republic of Kazakhstan; 182 patients from the groups facing the high risk of developing active tuberculosis received preventive tuberculosis treatment with new regimens: 71 patients were treated with isoniazid and rifampicin for 3 months (3 HR), 55 - with isoniazid and rifapentine for 1 month (1 HR), 56 - with levofloxacin for 6 months (6 Lfx).
Results. During treatment with regimens 3 HR, 1 HP, 6 Lfx, no adverse events of severity degree 3-4 developed , while adverse events of severity degree 1-2 were rare and relieved. The patient-oriented approach to the organization of preventive chemotherapy made it possible to achieve high treatment completion rates: in the group receiving 3 HR, it was 97.2% of cases, in the group receiving 1 HP - 96.4%, and in the group receiving 6 Lfx - 82.2%.
About the Authors
Zh. T. Zhandauletova
Public Foundation MAD Consulting
Kazakhstan
Kazakhstan
Zhanna T. Zhandauletova, Director
Room 404/1, 188 Dostyk Ave, Almaty, 050010
Phone: +7 (727) 259-90-41
E. I. Nikishova
Northern State Medical University
Russian Federation
Russian Federation
Elena I. Nikishova, Professor of Phthisiopulmonology Department
28 Novgorodsky Ave., Arkhangelsk, 163000
Phone: +7 (962) 664-81-67
A. O. Maryandyshev
Northern State Medical University; Northern (Arctic) Federal University named after M. V. Lomonosov
Russian Federation
Russian Federation
Andrey O. Maryandyshev, Head of Phthisiopulmonology Department
28 Novgorodsky Ave., Arkhangelsk, 163000
Phone: +7 (952) 306-02-38
K. S. Serikbaeva
National Research Center of Phthisiopulmonology, Ministry of Health of the Kazakhstan Republic
Kazakhstan
Kazakhstan
Kagaz S. Serikbaeva, Head of Department for Treatment of Tuberculosis and Drug Resistant Tuberculosis in Children
5 Bekkhozhina St., Almaty, 050010
Phone: +7 (727) 291-60-92
M. M. Adenov
National Research Center of Phthisiopulmonology, Ministry of Health of the Kazakhstan Republic
Kazakhstan
Kazakhstan
Malik M. Adenov Director
5 Bekkhozhina St., Almaty, 050010
Phone: +7 (727) 291-86-57
Sh. Sh. Ismailov
Project Implementation Group, Global Fund to Fight AIDS, Tuberculosis and Malaria
Kazakhstan
Kazakhstan
Shakhimurat Sh. Ismailov, Manager
Almaty
Phone: +7 (727) 293-80-00
Zh. A. Sapieva
Phthisiopulmonology Center
Kazakhstan
Kazakhstan
Zhanar A. Sapieva, Director
45 Degdar St., Almaty, 050010
Phone: +7 (727) 383-76-82
A. A. Trusov
Public Foundation MAD Consulting
United States
United States
Alexander Trusov
250 Gorge Road, 8c, Cliffside Park, New Jersey, 07010
Phone: +1 (201) 724-8177
G. A. Musabekova
Project Implementation Group, Global Fund to Fight AIDS, Tuberculosis and Malaria
Kazakhstan
Kazakhstan
Gulnaz Musabekova, Coordinator
Almaty
Phone: +7 (727) 291-91-92
S. Zh. Kasymbekova
Kazakh Scientific Center of Dermatology and Infectious Diseases, Ministry of Health of the Kazakhstan Republic
Kazakhstan
Kazakhstan
Sayrankul Zh. Kasymbekova, Head of Clinical Monitoring Department
60 Rayymbeka Ave., Almaty, 050000
Phone: +7 (727) 397-41-90
A. S. Rakisheva
Kazakh National Medical University named after S. D. Asfendiyarov
Kazakhstan
Kazakhstan
Anar S. Rakisheva, Professor of Phthisiopulmonology Department
94 Tole Bi St., Almaty, А05Н2А6
Phone: +7 (777) 237-61-16
References
1. Obnovlennoye svodnoye rukovodstvo po programmnomu vedeniyu sluchayev latentnoy tuberkuleznoy infektsii. (Russ. Ed.: Latent tuberculosis infection: updated and consolidated guidelines for programmatic management) Geneva, World Health Organisation, 2018. Available: https://apps.who.int/iris/bitstream/handle/10665/312059/9789245550235-rus.pdf
2. VOZ. Rukovodstvo po vedeniyu patsientov s latentnoy tuberkuleznoy infektsiey. (Russ. Ed.: Guidelines on the management of latent tuberculosis infection) Geneva, World Health Organisation, 2015. Available: https://apps.who.int/iris/bitstream/handle/10665/136471/9789244548905_rus.pdf
3. Alsdurf H., Hill P.C., Matteelli A., Getahun H., Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016; 16(11): 1269-78.
4. Badje A., Moh R., Gabillard D., Guéhi C., Kabran M., Ntakpé J.-B., et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017; 5(11): e1080-9.
5. Bamrah S., Brostrom R., Dorina F., Setik L., Song R., Kawamura L.M., Heetderks A., Mase S. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012 Int J Tuberc Lung Dis. 2014; 18(8): 912-918. http://dx.doi.org/10.5588/ijtld.13.0028
6. Cohen A., Mathiasen V.D., Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019; 54(3): 1900655.
7. Getahun H., Matteelli A., Chaisson R.E., Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015; 372(22): 2127-35.
8. Global tuberculosis report 2021. Available: https://www.who.int/publications/i/item/9789240037021
9. Gureva T., Turkova A., Yablokova E., Smirnova P., Sveshnikova O., Zolotaya O., Nikishova E., Heldal E., Hinderaker S., Seddon J.A., Mariandyshev A. Fluoroquinolone preventive therapy for children exposed to MDR-TB // Int J Tuberc Lung Dis. 2022; 26(2): 171-73.
10. Hamada Y., Ford N., Schenkel K., Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review. Int J Tuberc Lung Dis. 2018; 22(12): 1422-28.
11. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15: 603-22.
12. Pease C., Hutton B., Yazdi F., Wolfe D., Hamel C., Barbeau P., et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018; 27(6): 557-66.
13. Stagg H.R., Zenner D., Harris R.J., Muñoz L., Lipman M.C., Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann. Intern Med. 2014; 161(6): 419-28.
14. Swindells S., Ramchandani R., Gupta A., Benson C.A., Leon-Cruz J., Mwelase N., Jean Juste M.A. Lama J.R., Valencia J., Omoz-Oarhe A., Supparatpinyo K., Masheto G., Mohapi L., da Silva Escada R.O., Mawlana S., Banda P., Severe P., Hakim J., Kanyama C., Langat D., Moran L., Andersen J., Fletcher C.V., Nuermberger E., Chaisson R.E. for the BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Mar 14; 380(11): 1001-1011.
15. WHO consolidated guidelines on tuberculosis: Module 1: Tuberculosis preventive treatment / Geneva: World Health Organization; 2020. Available: https://apps.who.int/iris/bitstream/handle/10665/331170/9789240001503-eng
Review
For citations:
Zhandauletova Zh.T., Nikishova E.I., Maryandyshev A.O., Serikbaeva K.S., Adenov M.M., Ismailov Sh.Sh., Sapieva Zh.A., Trusov A.A., Musabekova G.A., Kasymbekova S.Zh., Rakisheva A.S. Safety of new tuberculosis treatment regimens and compliance with these regimens according to data from the Republic of Kazakhstan. Tuberculosis and Lung Diseases. 2023;101(1):17-26. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-1-17-26
Views:
974
Email this article 